Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 30;17(11):10348-10355.
doi: 10.21037/jtd-2025-1453. Epub 2025 Nov 26.

Delay in lung volume reduction surgery due to the COVID-19 pandemic: impact on patient performance and mortality

Alberte Lund  1 , Henrik J Hansen  1 , Kåre Hornbech  1 , Michael Perch  2   3 , Anna Kalhauge  4 , Jann Mortensen  3   5 , Kristine Jensen  2 , René H Petersen  1   3
Affiliations

Delay in lung volume reduction surgery due to the COVID-19 pandemic: impact on patient performance and mortality

Alberte Lund et al. J Thorac Dis. .

Abstract

Background: Severe chronic obstructive pulmonary disease (COPD) naturally progresses over time and is associated with increased mortality. During the coronavirus disease 2019 (COVID-19) pandemic, many surgical procedures were postponed, but the full impact of these delays remains unclear. Our aim was to evaluate the consequences of delayed lung volume reduction surgery (LVRS) treatment.

Methods: This study was conducted as a retrospective observational study. Patients who had LVRS postponed six months or more due to the COVID-19 pandemic at a national university centre were included. Data were obtained from an institutional database. Patients were re-evaluated before surgery using lung function tests, a 6-minute walking test (6MWT), and blood gas analysis. Increased symptoms, mortality, and infections were recorded. All surviving patients were reassessed for treatment indication in a multidisciplinary team (MDT) meeting.

Results: A total of 67 patients had their scheduled LVRS treatment postponed due to the pandemic. Of these 16% were infected with COVID-19. Four patients (6%) died before secondary evaluation. Mean time from outpatient clinic referral to surgery date was 398 (±161) days. Forced expiratory volume in one second (FEV1) significantly decreased by 0.1 L (P<0.001), while diffusion capacity of the lung for carbon monoxide (DLCO) remained unchanged. Performance in the 6MWT worsened by 29.9 m (P<0.001), and oxygen saturation decreased by 1.3% (P=0.046). Symptom worsening was experienced in 39% of patients. Clinical deterioration rendered 5% of patients unfit for surgery, while 86% remained fit for surgery. No patients were excluded due to COVID-19 infection.

Conclusions: The delay of LVRS due to the COVID-19 pandemic led to a decrease in lung function, 6MWT performance, and oxygen saturation. Although the majority of patients remained fit for surgery, the postponement resulted in cancellation of procedures due to clinical deterioration and contributed to waiting list mortality. This patient group is vulnerable to further deterioration over time and timely treatment should be prioritized.

Keywords: Coronavirus disease 2019 (COVID-19); chronic obstructive pulmonary disease (COPD); delay in treatment; emphysema; lung volume reduction surgery (LVRS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1453/coif). R.H.P. serves as an unpaid editorial board member of Journal of Thoracic Disease from October 2024 to September 2026. All authors report that this study was supported by a research grant from Medtronic. R.H.P. received speaker fees from Medtronic, AMBU, Medela, AstraZeneca and participated on advisory board for AstraZeneca, MSD, Roche, Bristol Meyers Squibb. K.J. received speaker fees from Medtronic. M.P. received a research grant from Roche and PulmonX, speaker fees from PulmonX, Novartis, Chiesi, AstaZeneca, Takeda, Therakos and support for congress attending from Boeringer-Ingelheim. H.J.H. received a research grant from BD and speaker fees from Medtronic. The authors have no other conflicts of interest to declare.

Figures

Figure 1
Figure 1
MDT decision after postponement and secondary evaluation. Other, aggravation of preexisting condition such as increased prednisolone use for bronchitis or increased golimumab dose for rheumatoid arthritis, etc. MDT, multidisciplinary team.
See this image and copyright information in PMC

References

    1. DeCamp MM, McKenna RJ, Deschamps CC, et al. Lung Volume Reduction Surgery: Technique, Operative Mortality, and Morbidity. Proc Am Thorac Soc 2008;5:442-6. 10.1513/pats.200803-023ET - DOI - PMC - PubMed
    1. Weder W, Tutic M, Lardinois D, et al. Persistent benefit from lung volume reduction surgery in patients with homogeneous emphysema. Ann Thorac Surg 2009;87:229-37. 10.1016/j.athoracsur.2008.10.012 - DOI - PubMed
    1. Russi EW, Bloch KE, Weder W. Lung volume reduction surgery: what can we learn from the National Emphysema Treatment Trial? Eur Respir J 2003;22:571–3. 10.1183/09031936.03.00077503 - DOI - PubMed
    1. Dansk register for Kronisk Obstruktiv Lungesygdom årsrapport. Available online: https://www.sundk.dk/media/i1jnskdv/drkol_a-rsrapport-2024_offentlig.pdf
    1. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017;5:691-706. 10.1016/S2213-2600(17)30293-X - DOI - PMC - PubMed